Targeting a Uniquely Nonspecific Prenyl Synthase with Bisphosphonates to Combat Cryptosporidiosis

被引:34
作者
Artz, Jennifer D. [1 ]
Dunford, James E. [2 ,3 ]
Arrowood, Michael J. [4 ]
Dong, Aiping [1 ]
Chruszcz, Maksymilian [5 ]
Kavanagh, Kathryn L. [2 ]
Minor, Wladek [5 ]
Russell, R. Graham G. [3 ]
Ebetino, F. Hal [6 ]
Oppermann, Udo [2 ,3 ]
Hui, Raymond [1 ]
机构
[1] Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L7, Canada
[2] Univ Oxford, Struct Genom Consortium, Oxford OX3 7DQ, England
[3] Univ Oxford, Inst Musculoskeletal Sci, Nuffield Dept Orthopaed Surg, Botnar Res Ctr, Oxford OX3 7LD, England
[4] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA
[5] Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA
[6] Procter & Gamble Pharmaceut Inc, Mason, OH 45040 USA
来源
CHEMISTRY & BIOLOGY | 2008年 / 15卷 / 12期
基金
英国惠康基金;
关键词
D O I
10.1016/j.chembiol.2008.10.017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cryptosporidiosis is a neglected disease without a wholly effective drug. We present a study demonstrating nitrogen-containing bisphosphonates (N-BPs) to be capable of inhibiting Cryptosporidium parvum at low micromolar concentrations in infected MDCK cells. Predictably, the mechanism of action is based on inhibition of biosynthesis of isoprenoids but the target enzyme is unexpectedly a distinctive C. parvum enzyme dubbed nonspecific polyprenyl pyrophosphate synthase (CpNPPPS). This enzyme produces various isoprenoid products larger than FPP and is inhibited by N-BPs at subnanomolar concentrations. It is part of an isoprenoid pathway in Cryptosporidium distinctly different from other organisms. The proposed mechanism of action is corroborated by crystal structures of the enzyme with risedronate and zoledronate bound showing how this enzyme's unique chain length determinant region enables it to accommodate larger substrates and products. These results, combined with existing data on their clinical use, demonstrate that N-BPs are very promising anticryptosporidial drug candidates.
引用
收藏
页码:1296 / 1306
页数:11
相关论文
共 56 条
[1]  
Arrowood Michael J., 2007, P499, DOI 10.1201/9781420052275.ch20
[2]   In vitro cultivation of Cryptosporidium species [J].
Arrowood, MJ .
CLINICAL MICROBIOLOGY REVIEWS, 2002, 15 (03) :390-+
[3]   ISOLATION OF CRYPTOSPORIDIUM OOCYSTS AND SPOROZOITES USING DISCONTINUOUS SUCROSE AND ISOPYCNIC PERCOLL GRADIENTS [J].
ARROWOOD, MJ ;
STERLING, CR .
JOURNAL OF PARASITOLOGY, 1987, 73 (02) :314-319
[4]  
ARROWOOD MJ, 1994, J EUKARYOT MICROBIOL, V41, pS23
[5]  
ARROWOOD MJ, 1996, J EUKARYOT MICROBIOL, V43, P89
[6]   Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase [J].
Bergstrom, JD ;
Bostedor, RG ;
Masarachia, PJ ;
Reszka, AA ;
Rodan, G .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 373 (01) :231-241
[7]   Effects of stunting, diarrhoeal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study [J].
Berkman, DS ;
Lescano, AG ;
Gilman, RH ;
Lopez, S ;
Black, MM .
LANCET, 2002, 359 (9306) :564-571
[8]   Crystal structure of type-III geranylgeranyl pyrophosphate synthase from Saccharomyces cerevisiae and the mechanism of product chain length determination [J].
Chang, Tao-Hsin ;
Guo, Rey-Ting ;
Ko, Tzu-Ping ;
Wang, Andrew H. -J. ;
Liang, Po-Huang .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (21) :14991-15000
[9]  
CHEN AJ, 1993, J BIOL CHEM, V268, P11002
[10]   Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies [J].
Chou, Ting-Chao .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :621-681